Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
GAITHERSBURG, Md., May 01, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2017 financial and operating results following the close of U.S. financial markets on Monday, May 8, 2017.
Conference call details are as follows:
| Date: | Monday, May 8, 2017 | ||
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | ||
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | ||
| Passcode: | 15607801 | ||
| Webcast: | www.novavax.com, “Investors”/ “Events” | ||
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 8, 2017, until 7:30 p.m. ET, May 15, 2017 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | ||
| Passcode: | 15607801 | ||
| Webcast: | www.novavax.com, “Investors”/ “Events” | ||
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
